Armando E. Giuliano

Armando E. Giuliano

Auto-generated profile, based on publicly available information

Armando E. Giuliano

John Wayne Cancer Institute

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2011 in JAMA
Verified
Journal Article
Open access
PDF file
AGArmando E. Giuliano
Armando E. Giuliano
KHKelly K. Hunt
Kelly K. Hunt
KBKarla V. Ballman
Karla V. Ballman
PBPeter D. Beitsch
Peter D. Beitsch
PWPat W. Whitworth
Pat W. Whitworth
MMMonica Morrow
Monica Morrow
Axillary lymph node dissection (ALND) has been part of breast cancer surgery since the description of the radical mastectomy.1 ALND reliably identifies nodal metastases and maintains regional control,2,3 but the contribution of local therapy to breast cancer survival is controversial.4,5 The Early Breast Cancer Trialists' Collaborative Group synthesized findings from 78 randomized controlled trials, concluding that local control of breast cancer was associated with improved disease-specific survival.6

1 September 2010 in Annals of Surgery
Verified
Journal Article
Closed access
AGArmando E. Giuliano
Armando E. Giuliano
LMLinda McCall
Linda McCall
PBPeter Beitsch
Peter Beitsch
PWPat W. Whitworth
Pat W. Whitworth
PBPeter Blumencranz
Peter Blumencranz
KBKarla Ballman
Karla Ballman
Sentinel lymph node dissection (SLND) has eliminated the need for axillary dissection (ALND) in patients whose sentinel node (SN) is tumor-free. However, completion ALND for patients with tumor-involved SNs remains the standard to achieve locoregional control. Few studies have examined the outcome of patients who do not undergo ALND for positive SNs. We now report local and regional recurrence information from the American College of Surgeons Oncology Group Z0011 trial. American College of Surgeons Oncology Group Z0011 was a prospective trial examining survival of patients with SN metastases detected by standard H and E, who were randomized to undergo ALND after SLND versus SLND alone without specific axillary treatment. Locoregional recurrence was evaluated. There were 446 patients randomized to SLND alone and 445 to SLND + ALND. Patients in the 2 groups were similar with respect to age, Bloom-Richardson score, estrogen receptor status, use of adjuvant systemic therapy, tumor type, T stage, and tumor size. Patients randomized to SLND + ALND had a median of 17 axillary nodes removed compared with a median of only 2 SN removed with SLND alone (P < 0.001). ALND also removed more positive lymph nodes (P < 0.001). At a median follow-up time of 6.3 years, there were no statistically significant differences in local recurrence (P = 0.11) or regional recurrence (P = 0.45) between the 2 groups. Despite the potential for residual axillary disease after SLND, SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.

2 March 2006 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LWLee Gravatt Wilke
Lee Gravatt Wilke
LMLinda M. McCall
Linda M. McCall
KPKatherine E. Posther
Katherine E. Posther
PWPat W. Whitworth
Pat W. Whitworth
DRDouglas S. Reintgen
Douglas S. Reintgen
AGArmando E. Giuliano
Armando E. Giuliano

1 July 2000 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AGArmando E. Giuliano
Armando E. Giuliano
PHPhilip I. Haigh
Philip I. Haigh
MBMeghan B. Brennan
Meghan B. Brennan
NHNora M. Hansen
Nora M. Hansen
MKMark C. Kelley
Mark C. Kelley
RTRoderick R. Turner
Roderick R. Turner
PURPOSE: Immediate complete axillary lymphadenectomy (ALND) after sentinel lymphadenectomy (SLND) has confirmed that tumor-negative sentinel nodes accurately predict tumor-free axillary nodes in breast cancer. Therefore, we hypothesized that SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with minimal complications. PATIENTS AND METHODS: Between October 1995 and July 1997, 133 consecutive women who had primary invasive breast tumors clinically ≤ 4 cm in diameter and no axillary lymphadenopathy were prospectively entered onto a trial of SLND using vital blue dye. Sentinel nodes were examined by standard microscopy or immunohistochemistry. SLND was the only axillary surgery if sentinel nodes were tumor-free. Completion ALND was performed only if sentinel nodes contained metastases or if they were not identified. Excluded from subsequent analysis were patients with unsuspected multifocal carcinoma and those who refused completion ALND. The complication and axillary recurrence rates after SLND without ALND were determined. RESULTS: Sentinel nodes were identified in 132 (99%) of 133 patients. Eight patients were excluded from further analysis. Of the 125 assessable patients, 57 had tumor-positive sentinel nodes and one had an unsuccessful mapping procedure; these patients underwent completion ALND. In the remaining 67 patients (54%), SLND was the only axillary procedure. Complications occurred in 20 patients (35%) undergoing ALND after SLND but in only two patients (3%) undergoing SLND alone (P = .001). There were no local or axillary recurrences at a median follow-up of 39 months. CONCLUSION: Complication rates are negligible after SLND alone. An absence of axillary recurrences supports SLND as an accurate staging alternative for breast cancer and suggests that routine ALND can be eliminated for patients with histopathologically negative sentinel nodes.

1 March 2014 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MMMeena S. Moran
Meena S. Moran
SSStuart J. Schnitt
Stuart J. Schnitt
AGArmando E. Giuliano
Armando E. Giuliano
JHJay R. Harris
Jay R. Harris
Seema Ahsan KhanSeema Ahsan Khan
Seema Ahsan Khan
MMMonica Morrow
Monica Morrow

17 February 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NWNabil Wasif
Nabil Wasif
MMMelinda A. Maggard
Melinda A. Maggard
CKClifford Y. Ko
Clifford Y. Ko
AGArmando E. Giuliano
Armando E. Giuliano